ImageneBio, Inc.
Close on Oct 19, 2026
- Market cap
- $64.65M
- P/E (TTM)
- –
- Dividend yield
- –
About ImageneBio
Biological Products, (No Diagnostic Substances), SIC 2836
ImageneBio, Inc. is a clinical-stage biopharmaceutical company that develops therapeutics for patients suffering from immunological, autoimmune, and inflammatory diseases. The company's lead product candidate is IMG-007, an investigational non-depleting anti-OX40 monoclonal antibody designed to selectively bind the OX40 receptor on activated T cells to block interactions with the OX40 ligand. Through this mechanism, the candidate attenuates pathological T-cell signaling across multiple inflammatory pathways without depleting T cells. ImageneBio focuses its initial clinical development of IMG-007 on patients with atopic dermatitis, while exploring potential utility in additional conditions such as alopecia areata, asthma, rheumatoid arthritis, and hidradenitis suppurativa.
The company conducts clinical trials across multiple countries, including an ongoing dose-finding Phase 2b clinical trial evaluating IMG-007 in patients with atopic dermatitis across sites in North America and other international locations. ImageneBio maintains its principal executive offices in San Diego, California.
Summary of the business section of ImageneBio's latest annual report, written by StockData.
Company profile
Company
- Legal name
- ImageneBio, Inc.
- Headquarters
- San Diego, CA
- Address
- 12526 High Bluff Drive 92130
- Phone
- (857) 343-8292
- Employees
- 15, Dec 31, 2025
- Industry
- Biological Products, (No Diagnostic Substances)
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- PricewaterhouseCoopers LLP, San Diego, California
Stock & identifiers
- Ticker
- IMA
- Exchange
- Nasdaq
- IPO date
- Mar 26, 2021
- Shares outstanding
- 11M, Jul 31, 2026
- Public float
- $41.70M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- Stock splits
- 1-for-12 reverse, Jul 28, 2025
- SEC CIK
- 1835579
- CUSIP
- 45175G207
- ISIN
- US45175G2075
- EIN
- 81-1697316
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Kristin Yarema | Chief Executive Officer, Director | 493,705 |
| Yanina Grant-Huerta | Chief Financial Officer | 65,000 |
| Robert B. Lally | Principal Accounting Officer | 55,582 |
| Benjamin Porter-Brown | Chief Medical Officer | – |
| Erin Butler | Principal Accounting Officer | 25,551 |
| Yufang Lu | Chief Medical Officer | – |
| Jotin Marango | Chief Financial Officer | 15,776 |
| Joseph P. Slattery | Director | 16,000 |
| Otello Stampacchia | Director | 455,361 |
| David P. Bonita | Director | 753,441 |
| Jonathan Jian Wang | Director | 1,115,005 |
| Wei-guo Su | Director | – |
| Advisors Llc Orbimed | Director | 287,885 |
| Capital GP VI LLC OrbiMed | Director | 2,251,218 |
| Genesis GP LLC OrbiMed | Director | 753,062 |
| Stephen Hui Wang | Director | 250,721 |
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 15 full-time employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Aug 12, 2025 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Aug 5, 2025 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Jul 29, 2025 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Jul 25, 2025 | Name change | Name changed from Ikena Oncology, Inc. to ImageneBio, Inc. |
| Mar 18, 2025 | Merger | Registration of securities for a merger or exchange offer (S-4) |
| Aug 7, 2023 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Jun 30, 2023 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Mar 26, 2021 | IPO | Initial public offering priced (424B4 prospectus) |
| Mar 23, 2021 | Listing | Registration of securities on an exchange (Form 8-A) |